Sino Biological Respiratory Virus Research Toolkit
 

Anti-SARS-CoV-2 QuantiVac ELISA (IgG)

Anti-SARS-CoV-2 QuantiVac ELISA IgG

Principle: Quantitative ELISA based on recombinant S1/RBD

Automation: YES

Approvals: CE-IVD

Suitability: Supports assessment of the level of immune reaction after SARS-CoV-2 infection or vaccination

Description:

Quantitative ELISA for determination of the concentration of IgG antibodies against the S1 antigen (including RBD) of SARS-CoV-2


Key Points:
  • 6-point calibration curve
  • Excellent correlation with the WHO international standard (NIBSC code: 20/136) – enabling issuing of results in standardised units
  • Very good agreement of results in comparison with different neutralisation tests
  • Validated for serum, plasma and dried capillary blood as sample material
  • Fully automatable

Areas:

    Clinical
Company contact details:

EUROIMMUN AG view full details
Lübeck
Germany

Website: Visit Website
Tel: +49 451 2032-0